Literature DB >> 33444321

Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.

Jason Ptacek1, Rachael E Hawtin1, Dongmei Sun2, Brent Louie1, Erik Evensen1, Barbara B Mittleman1, Alessandra Cesano1, Guy Cavet1, Clifton O Bingham3, Stacey S Cofield2, Jeffrey R Curtis2, Maria I Danila2, Chander Raman2, Richard A Furie4, Mark C Genovese5, William H Robinson5, Marc C Levesque6, Larry W Moreland7, Peter A Nigrovic8, Nancy A Shadick8, James R O'Dell9, Geoffrey M Thiele9, E William St Clair10, Christopher C Striebich7, Matthew B Hale5, Houman Khalili4, Franak Batliwalla4, Cynthia Aranow4, Meggan Mackay4, Betty Diamond4, Garry P Nolan1, Peter K Gregersen4, S Louis Bridges11.   

Abstract

Rheumatoid arthritis (RA) is a systemic and incurable autoimmune disease characterized by chronic inflammation in synovial lining of joints. To identify the signaling pathways involved in RA, its disease activity, and treatment response, we adapted a systems immunology approach to simultaneously quantify 42 signaling nodes in 21 immune cell subsets (e.g., IFNα→p-STAT5 in B cells) in peripheral blood mononuclear cells (PBMC) from 194 patients with longstanding RA (including 98 patients before and after treatment), and 41 healthy controls (HC). We found multiple differences between patients with RA compared to HC, predominantly in cytokine-induced Jak/STAT signaling in many immune cell subsets, suggesting pathways that may be associated with susceptibility to RA. We also found that high RA disease activity, compared to low disease activity, was associated with decreased (e.g., IFNα→p-STAT5, IL-10→p-STAT1) or increased (e.g., IL-6STAT3) response to stimuli in multiple cell subsets. Finally, we compared signaling in patients with established, refractory RA before and six months after initiation of methotrexate (MTX) or TNF inhibitors (TNFi). We noted significant changes from pre-treatment to post-treatment in IFNα→p-STAT5 signaling and IL-10→p-STAT1 signaling in multiple cell subsets; these changes brought the aberrant RA signaling profiles toward those of HC. This large, comprehensive functional signaling pathway study provides novel insights into the pathogenesis of RA and shows the potential of quantification of cytokine-induced signaling as a biomarker of disease activity or treatment response.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33444321      PMCID: PMC7808603          DOI: 10.1371/journal.pone.0244187

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  42 in total

1.  Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.

Authors:  Clio P Mavragani; Dan T La; William Stohl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2010-02

2.  Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells.

Authors:  Jingsong Wang; John W Fathman; Geanncarlo Lugo-Villarino; Lucila Scimone; Ulrich von Andrian; David M Dorfman; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2006-01-12       Impact factor: 14.808

3.  Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus.

Authors:  Scott A Jenks; Kevin S Cashman; Esther Zumaquero; Urko M Marigorta; Aakash V Patel; Xiaoqian Wang; Deepak Tomar; Matthew C Woodruff; Zoe Simon; Regina Bugrovsky; Emily L Blalock; Christopher D Scharer; Christopher M Tipton; Chungwen Wei; S Sam Lim; Michelle Petri; Timothy B Niewold; Jennifer H Anolik; Greg Gibson; F Eun-Hyung Lee; Jeremy M Boss; Frances E Lund; Ignacio Sanz
Journal:  Immunity       Date:  2018-10-09       Impact factor: 31.745

4.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis; Joan M Bathon; E William St Clair; S Louis Bridges; Jie Zhang; Theresa McVie; George Howard; Désirée van der Heijde; Stacey S Cofield
Journal:  Arthritis Rheum       Date:  2012-09

Review 5.  Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications.

Authors:  Todd M Covey; Alessandra Cesano
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-10       Impact factor: 3.020

6.  Expression of Interferon-γ Receptor Genes in Peripheral Blood Mononuclear Cells Is Associated With Rheumatoid Arthritis and Its Radiographic Severity in African Americans.

Authors:  Qi Tang; Maria I Danila; Xiangqin Cui; Lauren Parks; Brandi J Baker; Richard J Reynolds; Chander Raman; Keith C Wanseck; David T Redden; Martin R Johnson; S Louis Bridges
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

7.  IFNγ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation.

Authors:  Esther Zumaquero; Sara L Stone; Christopher D Scharer; Scott A Jenks; Anoma Nellore; Betty Mousseau; Antonio Rosal-Vela; Davide Botta; John E Bradley; Wojciech Wojciechowski; Travis Ptacek; Maria I Danila; Jeffrey C Edberg; S Louis Bridges; Robert P Kimberly; W Winn Chatham; Trenton R Schoeb; Alexander F Rosenberg; Jeremy M Boss; Ignacio Sanz; Frances E Lund
Journal:  Elife       Date:  2019-05-15       Impact factor: 8.140

Review 8.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

9.  Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial.

Authors:  S L Morgan; J E Baggott; W H Vaughn; J S Austin; T A Veitch; J Y Lee; W J Koopman; C L Krumdieck; G S Alarcón
Journal:  Ann Intern Med       Date:  1994-12-01       Impact factor: 25.391

10.  Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

Authors:  Lisa Gm van Baarsen; Carla A Wijbrandts; François Rustenburg; Tineke Cantaert; Tineke Ctm van der Pouw Kraan; Dominique L Baeten; Ben Ac Dijkmans; Paul P Tak; Cornelis L Verweij
Journal:  Arthritis Res Ther       Date:  2010-01-22       Impact factor: 5.156

View more
  4 in total

1.  Network pharmacology-based approach uncovers the JAK/STAT signaling mechanism underlying paederia scandens extract treatment of rheumatoid arthritis.

Authors:  Bo-Cen Chen; He-Yu He; Kun Niu; Kai Rui; Ji-Gen Huang; Yi-Qiang Xie; Man Xiao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Herbal Formula Longteng Decoction Promotes the Regression of Synovial Inflammation in Collagen-Induced Arthritis Mice by Regulating Type 2 Innate Lymphocytes.

Authors:  Huijie Zhang; Juan Liu; Pingxin Zhang; Dongyang Li; Guiyu Feng; Meiyier Huandike; Song Sun; Limin Chai; Jingwei Zhou
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

3.  A Crowdsourcing Approach to Develop Machine Learning Models to Quantify Radiographic Joint Damage in Rheumatoid Arthritis.

Authors:  Dongmei Sun; Thanh M Nguyen; Robert J Allaway; Jelai Wang; Verena Chung; Thomas V Yu; Michael Mason; Isaac Dimitrovsky; Lars Ericson; Hongyang Li; Yuanfang Guan; Ariel Israel; Alex Olar; Balint Armin Pataki; Gustavo Stolovitzky; Justin Guinney; Percio S Gulko; Mason B Frazier; Jake Y Chen; James C Costello; S Louis Bridges
Journal:  JAMA Netw Open       Date:  2022-08-01

4.  Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family.

Authors:  Amir Taldaev; Vladimir R Rudnev; Kirill S Nikolsky; Liudmila I Kulikova; Anna L Kaysheva
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.